Amgen Kicks Off Pembrolizumab Program As It Delivers Q1 Results

ABP234 Proposed Keytruda Rival Is Latest Asset For Amgen’s Biosimilars Business

May 03 2024

• By David Wallace

Amgen has disclosed a biosimilar Keytruda program • Source: Shutterstock

More from Biosimilars

More from Products